NASDAQ$HLVX
HilleVax Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2024 and highlighted recent progress.
HilleVax reported a net loss of $40.7 million for the second quarter of 2024. The company had $245.0 million in cash, cash equivalents, and marketable securities as of June 30, 2024. They discontinued further development of HIL-214 in infants and announced a workforce reduction of approximately 40%.
- NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, leading to discontinuation of HIL-214 development in infants.
- Announced a workforce reduction of approximately 40% to reduce operating expenses.
- Exploring potential continued development of HIL-214 and HIL-216 norovirus vaccine candidates in adults.
- Cash, cash equivalents and marketable securities totaled $245.0 million as of June 30, 2024.
Headline financials
Revenue & EPS history
HilleVax · Revenue · Quarterly
$0
Forward guidance
HilleVax is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine candidates in adults.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports · overlaid with Q2 2024
-3.3%
Avg return
Earnings day
-2.3%
Avg return
5 days after
-0.9%
Avg return
30 days after
22%
4 / 18 earnings
Positive
+7.9%
Q4 2024
Best reaction
-16.7%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +0.5% | +0.5% | +2.0% | |
| Q1 2025 | -1.0% | -5.6% | -6.7% | |
| Q4 2024 | +7.9% | -10.1% | +17.0% | |
| Q3 2024 | -2.6% | +1.6% | +2.6% | |
| Q2 2024 | -0.6% | +5.7% | +8.2% | |
| Q1 2024 | +2.7% | -3.0% | +0.2% | |
| Q4 2023 | -9.0% | -5.4% | -29.5% | |
| Q3 2023 | +1.5% | — | — | |
| Q2 2023 | -16.7% | — | — | |
| Q1 2023 | -1.2% | — | — | |
| Q4 2022 | -12.1% | — | — | |
| Q3 2022 | -8.2% | — | — | |
| Q3 2021 | -8.2% | — | — | |
| Q2 2021 | -6.5% | — | — | |
| Q2 2022 | -6.5% | — | — | |
| Q1 2022 | +0.0% | — | — | |
| Q1 2021 | +0.0% | — | — | |
| Q4 2021 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro